Vonoprazan, a potassium-competitive acid blocker, has shown potential to improve nighttime gastroesophageal reflux symptoms in adults with nonerosive reflux disease (NERD). New data published in The American Journal of Gastroenterology indicates that the medication increased symptom-free nights and reduced the severity of nocturnal reflux compared to a placebo. The study focused on patients who experience heartburn and regurgitation after going to bed, a condition that is often difficult to manage with existing therapies.
Lead author Catiele Antunes, MD, an assistant professor of medicine and director of the Refractory GERD Clinic at Yale School of Medicine, highlighted the clinical gap this trial addresses. “Very often patients have symptoms at nighttime, and a lot of times these symptoms are not necessarily very easy to manage,” she said. Antunes noted that previous research on available medications has not consistently evaluated their specific role in treating nighttime reflux, leaving clinicians without robust data for this specific patient population.
Trial Design and Initial Outcomes
The randomized, double-blind trial included 772 adults across 91 centers in the United States. All participants suffered from reflux symptoms at least four days per week and showed no evidence of erosive disease on endoscopy.
For four weeks, participants were assigned to one of three groups: a placebo group, a group receiving 10 mg of vonoprazan once daily, or a group receiving 20 mg of vonoprazan once daily.
At the end of the four-week period, the results were distinct. Participants in the placebo group reported an average of 43.3% symptom-free nights. In contrast, those taking the 10 mg dose achieved an average of 59.9% symptom-free nights, while the 20 mg group reported 56.4%. These figures suggest that the lower dose may have been slightly more effective in this specific metric, though both active arms outperformed the placebo significantly.
Researchers also utilized the Nocturnal Gastroesophageal Reflux Disease Symptom Severity and Impact Questionnaire (N-GSSIQ) to measure symptom burden. The questionnaire assessed factors like heartburn after bed, regurgitation, and the frequency of waking up due to reflux. Participants in the vonoprazan groups recorded lower overall N-GSSIQ scores than the placebo group, with statistically significant improvements in both the 10 mg and 20 mg cohorts.
The rapid onset of action is a notable feature of this drug class. Antunes observed that patients often notice a benefit after just the first or second dose. “Usually after even the first or second dose of this medication, they can already notice a benefit, so you don’t need to wait until it builds up a [higher] level in the blood. It works very quickly,” she explained. This speed could be advantageous for patients seeking immediate relief from disruptive sleep interruptions, rather than waiting for a therapeutic plateau that characterizes other acid-suppressive agents.
Long-Term Relief and Questionnaire Scores
The study included a 24-week extension phase to assess the durability of these effects. Those who had initially received a placebo were randomly assigned to either the 10 mg or 20 mg vonoprazan group, while participants already on the medication continued their assigned dose.
By the end of the 24-week extension, the average rate of nights without heartburn was similar among the four groups.
Changes in N-GSSIQ scores from baseline also favored the vonoprazan groups. These negative values indicate a reduction in symptom severity and impact compared to the start of the trial.
Clinical Context and Limitations
While the results are positive for vonoprazan, experts caution against over-interpreting the data in relation to other treatments. Patrick Hyatt, MD, director of The Center for Heartburn and Reflux Disease in Baltimore, emphasized that the trial did not include a head-to-head comparison between vonoprazan and traditional proton pump inhibitors (PPIs) like omeprazole or lansoprazole.
However, he noted that clinicians should avoid concluding that vonoprazan is superior to PPIs based solely on this data, as no direct comparison was made.
Hyatt also highlighted the utility of the N-GSSIQ as a diagnostic tool. He suggested that the questionnaire helps patients identify nocturnal reflux, which might be linked to daytime issues like fatigue or sleep disturbances. “It’s something to speak to their physicians about and say, ‘Could I be suffering from nocturnal reflux?’ and if so, to seek further investigation, because it’s important to rule that out,” he said.
Vonoprazan, marketed as Voquezna, was first approved by the US Food and Drug Administration in November 2023 for erosive GERD and later expanded its label in July 2024 to include relief of heartburn associated with NERD.